Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026
Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026
Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Fineline Cube Jan 23, 2026

Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026

Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...

Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026

Sisram Medical Ltd (HKG: 1696), an Israel‑based beauty and wellness group and part of Fosun...

Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026

Becton, Dickinson and Co. (BD) and Swiss injection system developer Ypsomed announced an expanded collaboration...

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026

Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the extension of...

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immune‑inflammatory disease specialist founded in 2016, has filed for...

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Fineline Cube Jan 23, 2026

Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing...

Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026

AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved Risankizumab (SKYRIZI)...

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics...

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026

TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative...

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026

China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026

Matwings Technology, a pioneer in AI‑driven protein engineering, announced a strategic biopharmaceutical pipeline collaboration with...

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026

Tianjin AmCellGene Co., Ltd. has granted Hong Kong‑based Advanced Regeneration exclusive regional rights to commercialize...

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026

Huadong Medicine Co., Ltd. (SHE: 000963), a leading China‑based pharmaceutical group, announced an exclusive commercialization...

Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Fineline Cube Jan 22, 2026

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Fineline Cube Jan 22, 2026

Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...

Posts pagination

1 … 50 51 52 … 663

Recent updates

  • Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties
  • Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304
  • CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer
  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
  • CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.